Pharmacological Inhibition of LSD1 for Cancer Treatment
Lysine-specific demethylase 1A (LSD1, also named KDM1A) is a demethylase that can remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is aberrantly expressed in many cancers, where it impedes differentiation and contributes to cancer cell proliferation, cell metastasis and invasiveness, a...
Main Authors: | Guan-Jun Yang, Pui-Man Lei, Suk-Yu Wong, Dik-Lung Ma, Chung-Hang Leung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/23/12/3194 |
Similar Items
-
Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer
by: Barbara Majello, et al.
Published: (2019-03-01) -
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
by: Yuan Fang, et al.
Published: (2019-12-01) -
Natural products as LSD1 inhibitors for cancer therapy
by: Yuan Fang, et al.
Published: (2021-03-01) -
The lasting influence of LSD1 in the blood
by: Sharon YR Dent, et al.
Published: (2013-06-01) -
Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation
by: Marc A Kerenyi, et al.
Published: (2013-06-01)